| November 3 |
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma |
| November 3 |
Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models |
| November 3 |
Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD) |
| November 3 |
Oncolytics Biotech Inc. Collaborators Present Positive Combination and Docetaxel Results at iSBTc Annual Meeting |
| November 3 |
Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination Reolysin and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting |
| November 3 |
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma |
| November 3 |
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial |
| November 3 |
Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008 |
| November 3 |
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B |
| November 3 |
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005 |
| November 3 |
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients |
| November 3 |
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder |
| November 3 |
Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development |
| November 3 |
New Study Demonstrated Actemra (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients |
| November 3 |
Top-Line Preliminary Data From Phase II/III Study of Corthera's Relaxin in Acute Heart Failure to be Presented in Satellite Symposium at AHA Scientific Sessions 2008 |
| November 3 |
Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia |
| November 3 |
Anti-VEGF Drugs for Retinal Diseases Could Have Serious Side Effects, Scientists Caution |
| November 3 |
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers |
| November 3 |
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection |
| November 3 |
Durezol in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented |
| November 3 |
PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress |
| November 3 |
New Data Suggest Long-Term Treatment with Baraclude (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B |
| November 4 |
NicOx announces favorable blood pressure data for naproxcinod in a large ABPM study |
| November 4 |
Phase IIa data on TMC435350 in patients with hepatitis C now presented at the ongoing AASLD |
| November 4 |
ZymoGenetics Presents Positive Interim Phase 1b Results in Hepatitis C |
| November 4 |
Vertex announces positive data at the annual AASLD meeting |
| November 4 |
YM Biosciences Reports Data From Exploratory Clinical Trials Of Nimotuzumab In Brain Metastases And High-Grade Glioma Presented At 2008 Eortc-Nci-Aacr Annual Meeting |
| November 4 |
Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Society's Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland) |
| November 4 |
AMA Journal Publishes Study Showing Evidence of a Major Environmental Trigger For Autism |
| November 4 |
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells |
| November 4 |
PRA International Addresses Sponsor-CRO Partnering Strategies at European Partnerships in Clinical Trials Congress |
| November 4 |
Generex Oral-lyn Featured at International Diabetes Conference |
| November 4 |
Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year |
| November 4 |
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study |
| November 5 |
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations |
| November 5 |
Ambrx to Present Phase I/II Clinical Data for Optimized, Long Acting Human Growth Hormone Analogue |
| November 5 |
SciClone and Sigma-Tau Report Phase 3 Hepatitis C Trial Results |
| November 5 |
AgilityBio and Advinus Announce Partnership to Introduce Digital Pathology Services in Pre Clinical Research |
| November 5 |
Centre Hospitalier Universitaire Vaudois, Swiss Vaccine Research Institute and Institut Genetique Moleculaire Montpellier: Study Sheds Light on the Mechanisms of Increased Risk of HIV Infection in the Step HIV Vaccine Trial |
| November 5 |
Five Synexus Sites Randomise More Than 1300 Patients in Three Weeks |
| November 5 |
Bio-Imaging Technologies Announces Third Quarter 2008 Financial Results |
| November 5 |
Zannos Grekos, MD to Present Clinical Results of Regenerative Stem Cell Treatments to the Dubai Congress on Anti-Aging and Aesthetic Medicine |
| November 6 |
PAREXEL Expands Pioneering Asian Ethnobridging Expertise |
| November 6 |
Bavarian Nordic reports successful safety data from Phase II study with Imvamune |
| November 6 |
Azilect Shown to Be a Selective MAO-B Inhibitor |
| November 6 |
Canopus BioPharma Announces Positive Results in Human Study of Novel Peptide Cancer Vaccine |
| November 6 |
Living Cell Technologies Reports on 12-Month Clinical Effects of DiabeCell at Annual General Meeting |
| November 6 |
Dendreon Presents Integrated Analysis of Clinical Data from Neuvenge Trials at Chemotherapy Foundation Symposium |
| November 6 |
Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008 |
| November 6 |
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review |
| November 6 |
Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics |
| November 6 |
Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile |
| November 6 |
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium |
| November 6 |
VIA Pharmaceuticals Announces Conference Call and Webcast to Discuss VIA-2291 Phase 2 Data Presentations at AHA |
| November 6 |
Proteon Therapeutics Presents New Data on PRT-201 at the Annual Meeting of the American Society of Nephrology in Philadelphia |
| November 6 |
Pervasis Therapeutics Presents Safety Data from Phase 1 and 2 Clinical Trials of Vascugel at the American Society of Nephrology Annual Meeting |
| November 6 |
Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients |
| November 6 |
Affymax Announces New Data Presented on the Long-Term Safety and Effectiveness of Hematide to Treat Anemia in Chronic Renal Failure Patients with Monthly Dosing |
| November 6 |
Acologix Presents Findings From the UREMIC PRURITIS National Registry Study at the 41st Annual Meeting of the American Society of Nephrology |
| November 6 |
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin |
| November 6 |
Oncolytics Biotech Inc. Investigators Present Interim U.S. Reolysin Phase II Sarcoma Trial Data |
| November 6 |
Cytochroma Announces Positive Comparative Data on CTA018 in Chronic Kidney Disease Model |
| November 6 |
Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHC is Safe in Combination With Most Chemotherapeutic Agents |
| November 6 |
DW Healthcare Partners Forms Best in Class Organization with ClinPro Inc. and Pacific Data Designs, LLC |
| November 6 |
LSR Announces Third Quarter Results |
| November 7 |
Full Results of Varisolve US Phase II Safety Study to be Presented at ACP |
| November 7 |
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer |
| November 7 |
Cytochroma Announces Positive Comparative Data on CTA018 |
| November 7 |
Kendle Named a 'Best Place to Work' in Greater Cincinnati |
| November 7 |
Sciele Pharma and Plethora Solutions Announce Positive Phase III Clinical Results of PSD502 for Premature Ejaculation |
| November 7 |
Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease |
| November 7 |
Pervasis Therapeutics Presents Data at American Society of Nephrology Meeting |
| November 7 |
Atrial Fibrillation Found to be Common in Patients With Atherothrombosis, Increases Risk of Cardiovascular Death, Heart Attack and Stroke |
| November 7 |
Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal |
| November 7 |
Data From Investigational Use of Procrit (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting |
| November 7 |
Theratechnologies Presents Additional Results from its Tesamorelin Phase 3 Studies at the 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV |
| November 7 |
iCo Therapeutics Oral Amphotericin B Effective Against Visceral Leishmaniasis |
| November 7 |
Santhera Presents Preclinical Data on Oral MC4 Receptor Antagonists for Treatment of Cancer Cachexia at AICR Research Conference |
| November 10 |
Aradigm Completes Study of Inhaled Treprostinil with AERx Inhaler |
| November 10 |
Memory Pharmaceuticals Announces Six Abstracts Accepted for Presentation at Society for Neuroscience Meeting |
| November 10 |
Crestor Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study |
| November 10 |
Zevalin Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma |
| November 10 |
EKC-Cide Study Results Presented at National Ophthalmology Meeting |
| November 10 |
Geron Scientists and Collaborators Demonstrate TAT2 - A Small Molecule Telomerase Activator - Enhances Antiviral Function of Immune Cells From HIV+ Donors |
| November 10 |
VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease |
| November 10 |
First-Ever Study Conducted Demonstrating Economic, Individual, and Societal Burden of Hereditary Angioedema |
| November 10 |
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial |
| November 10 |
Molecular Insight Pharmaceuticals, Inc. To Present Results from a Prospective Analysis of Zemiva Phase 2b Data at the 2008 Scientific Sessions of the American Heart Association |
| November 10 |
Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death |
| November 10 |
ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action |
| November 10 |
Study Shows Potential Benefits of Xolair in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids |
| November 10 |
Glaucoma Research and Patient Care Highlighted at American Academy of Ophthalmology Meeting |
| November 10 |
New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity |
| November 10 |
Celladon Announces Presentation of Clinical Data From First-in-Human Mydicar Trial for Advanced Heart Failure at American Heart Association Scientific Sessions |
| November 10 |
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease |
| November 10 |
UCLA Medical Researchers Report Brain Injury After Cardiac Arrest May Be Avoided |
| November 10 |
Crestor Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study |
| November 10 |
Results of Studies of Alvesco for the Treatment of Asthma and Omnaris in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting |
| November 10 |
Molecular Insight Announces Positive Results from a Prospective Analysis of Phase 2b Data for Zemiva in Emergency Department Setting |
| November 10 |
Research Identifies Predictors for Successful IVF |
| November 10 |
Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure |
| November 10 |
Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology |
| November 10 |
Rivaroxaban Phase II Dose-Ranging Study Demonstrates Encouraging Response Rates in Treatment of Acute Coronary Syndrome Patients |
| November 10 |
Largest Study Demonstrates Comparable Pregnancy Outcomes Using Vaginal Gel versus Injectable Progesterone, with Frozen Embryos from Donor Eggs |
| November 10 |
Santaris Pharma Releases Positive Data on LNA-based Survivin Inhibitor |
| November 10 |
Four Pralatrexate (PDX) Studies to Be Presented at the 50th Annual Meeting of the American Society of Hematology |
| November 10 |
Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial |
| November 10 |
Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH |
| November 10 |
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease |
| November 10 |
Ofatumumab Pivotal CLL Data to be Presented at ASH |
| November 11 |
Intestinal Infection Afflicts 13 of 1,000 Hospital Patients, Infection Rates 6.5 - 20 Times Greater Than Previous Estimates, New Study Says |
| November 11 |
RVX-208 Data Demonstrates Increase in Functional HDL Particles |
| November 11 |
Researchers to Present Additional Data on Soliris (eculizumab) for the Treatment of PNH at the ASH Annual Meeting |
| November 11 |
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint |
| November 11 |
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF |
| November 11 |
NEI Releases Complete Data From Age-Related Eye Disease Study |
| November 11 |
FibroGen Announces New Research on HIF-PHI and Anti-CTGF Development Programs in Chronic Kidney Disease |
| November 11 |
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601 |
| November 11 |
Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism |
| November 11 |
Potentia Presents Phase I Data on Leading AMD Drug at AAO |
| November 11 |
WomenHeart Urges Women to Talk With Doctors About New Study Showing Statins Prevent Heart Attacks, Deaths |
| November 11 |
Anesiva Announces Adlea ACTIVE-1 Phase 3 Clinical Results, Ceasing of Zingo Commercial Operations and Restructuring |
| November 11 |
CPEX Pharmaceuticals Announces Publication in Journal of Diabetes Science and Technology |
| November 11 |
Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80 |
| November 11 |
Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease |
| November 11 |
INNO-406 Demonstrates Positive Clinical Responses in Phase 1 Trial in Patients with Chronic Myeloid Leukemia |
| November 11 |
LCP-AtorFen Phase II Data to Be Presented at the American Heart Association's 2008 Scientific Sessions in New Orleans, LA, on November 11 |
| November 11 |
Triglyceride Levels Continue to Rise in the United States Despite Increased Use of Cholesterol-Lowering Medications |
| November 11 |
New Research of Amyloid Cardiomyopathy Fosters Better Understanding of Disease Progression |
| November 11 |
Lipocine Establishes Clinical Feasibility of Once-a-Day Ziprasidone |
| November 11 |
Testosterone Effective in Female Sexual Dysfunction; BioSante Conducting Long-Term Safety Study of LibiGel in FSD |
| November 11 |
IMM, Cenix, and Alnylam Discover New Targets in Malaria Infection with RNAi Technology |
| November 11 |
Published Study Demonstrates Oxycyte Can Improve Cognitive Recovery And Reduce Neuronal Cell Loss After Traumatic Brain Injury in Animal Model |
| November 11 |
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia Program |
| November 11 |
Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia |
| November 11 |
Drug-Eluting Stents Beat Bare Metal Stents in Diabetics |
| November 11 |
Dronedarone (Multaq) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation |
| November 11 |
Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein |
| November 11 |
Tailored Drug Delivery Reduces Adverse Effects After PCI |
| November 11 |
Study Finds Timing Is Everything For Some Heart Attack Patients |
| November 11 |
Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data |
| November 11 |
Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker |
| November 11 |
POZEN'S PA32520 Study Data Demonstrated Better Upper Gastrointestinal Protection |
| November 11 |
Interferon Reduces, Eliminates Viral Infections in Heart Failure Patients |
| November 11 |
MD Biosciences to Showcase Pre-Clinical Capabilities at the Neuroscience 2008 Conference |
| November 11 |
New study: A Common Class of GI Medications Reduce Protection Against Heart Attack in Patients Taking Widely Prescribed Cardiovascular Drug |
| November 11 |
APIC Covers Up Extent and Causes of Deadly C. diff |
| November 11 |
Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia |
| November 11 |
Rasilez, first-in-class direct renin inhibitor, provides greater reduction in high blood pressure than ACE inhibitor ramipril in patients 65 and older |
| November 11 |
Study Demonstrating Lovaza/Omacor Co-administered with Atorvastatin Reduces Non-HDL Cholesterol to be presented at AHA |
| November 12 |
Acusphere Announces Data Demonstrating Imagify Perfusion Stress Echo Predicts Presence of Coronary Artery Disease |
| November 12 |
American Academy of Ophthalmology Joint Meeting Marked by Strong Turnout and Rich Scientific Program |
| November 12 |
NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen |
| November 12 |
Titan Pharmaceuticals Announces Data Presentations for Probuphine at the 2008 International Society of Addiction Medicine Congress |
| November 12 |
Pervasis Therapeutics to Present Safety and Efficacy Data from Phase 1 and 2 Clinical Trials of Vascugel(R) at the 35th Annual VEITHsymposium(TM) |
| November 12 |
Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982 |
| November 12 |
ImmunoCellular Therapeutics Presents Data Demonstrating Immune Response Targeting Cancer Stem Cells |
| November 12 |
SCOLR Pharma, Inc. to Attend American Association of Pharmaceutical Scientists - AAPS - Annual Meeting and Exposition |
| November 12 |
Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix) Non-Responders |
| November 12 |
New Analysis Suggests That Improvements in Kidney Function in Patients Treated with Lipitor Strongly Correlate with a Reduced Risk of Major Cardiovascular Events |
| November 12 |
Nymox Reports Positive New Results in 59 Week Study of Drug for Enlarged Prostate |
| November 12 |
Tercica Announces Results from Increlex Phase IIIb Study Demonstrating Dose-Dependent Height Velocity Increase in Primary IGFD Short Stature Population and Other Increlex Studies at the 13th International Congress of Endocrinology Meeting |
| November 12 |
Ongoing Pregnancy Rates among Infertility Patients with Luteal Phase Bleeding No Different with Vaginal Gel or Injectable Progesterone |
| November 12 |
Benign or Cancerous? |
| November 12 |
Tibotec Data Presented at ICAAC and HIV9 Follow key Regulatory Approvals for Anti-HIV Compounds |
| November 12 |
Nymox Reports Positive New Results in 59 Week Study of Drug for Enlarged Prostate |
| November 12 |
Long-term study evaluates boosted Prezista vs. lopinavir/ritonavir as part of HIV combination therapy in treatment-naive adults |
| November 13 |
MorphoSys Publishes Preclinical Data from MOR103 Program |
| November 13 |
Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Successfully Completes Phase 1 Clinical Trials |
| November 13 |
Osteoporosis Drugs May Prevent Future Bone Growth |
| November 13 |
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study |
| November 13 |
Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences |
| November 13 |
Micromet to Present Interim Data from Two Studies for T Cell Engaging BiTE Antibody Blinatumomab at American Society of Hematology Annual Meeting |
| November 13 |
Gardasil, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study |
| November 13 |
Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated |
| November 13 |
Scientists Crack the Code to Tamoxifen Resistance |
| November 13 |
Seniors Can Be Heartened by New Study on Statins |
| November 13 |
Preclinical Study Presented at the International Congress of Endocrinology Shows Intravail Drug Delivery Technology Provides Unmatched Non-Invasive Delivery of an Anti-Obesity Peptide |
| November 13 |
Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months |
| November 13 |
ViroPharma Announces Presentation of Cinryze Data in Acute Treatment of Hereditary Angioedema |
| November 13 |
BioReliance Corporation Announces that Sarah Sheridan, Ph.D. Will Deliver a Poster Presentation at the 16th Annual European Society of Gene and Cell Therapy Conference |
| November 13 |
Avastin Gives an Additional Four Months of Life to Patients with One of the Most Common Types of Lung Cancer |
| November 14 |
ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III) for Treatment of Visual Disorders |
| November 14 |
Oncolytics Biotech Inc. Collaborators to Present Reolysin Research at CTOS Annual Meeting |
| November 14 |
Oxford BioMedica Announces Two Scientific Presentations of ProSavin in Parkinson's Disease |
| November 14 |
Oramed Pharmaceuticals Presents Results of Oral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs |
| November 14 |
New Data Points to Long Lasting Beneficial Effects of CEL-SCI's Rheumatoid Arthritis Vaccine |
| November 17 |
FREEDOM-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint |
| November 17 |
Alkermes Presents Positive Preclinical Data on Novel, ProprietaryMolecule Designed to Improve Outcomes for Patients Taking OpioidAnalgesics |
| November 17 |
Medivation Announces Upcoming Data Presentations on Dimebon's Mechanism of Action |
| November 17 |
Paloma Pharmaceuticals Publishing Seminal Paper in Cancer Research and Presentation at the AACR Special Conference in Cancer Research |
| November 17 |
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 |
| November 17 |
Patients Experienced Nearly a 70% Reduction in Pain When Using MPMMedical's Regenecare Wound Care Gel |
| November 17 |
ZIOPHARM Oncology Presents Positive Data from Studies of Palifosfamide |
| November 17 |
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% |
| November 17 |
Biodel Reports Protective Effects of VIAject Insulin on Microvascular Function in Patients with Type 2 Diabetes |
| November 17 |
ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008 |
| November 18 |
Long-Term TITAN Study Evaluates Prezista/ritonavir vs. lopinavir/ritonavir as Part of HIV Combination Therapy in Treatment-Experienced Adults |
| November 18 |
Cimzia (certolizumab pegol) Studies Show Significant Clinical Benefits for Mono- and Combination Therapy in Patients with Rheumatoid Arthritis |
| November 18 |
Company's MPACs for the Treatment of Alzheimer's Disease Shown to Prevent Neural Cell Death and the Production of Amyloid-Beta Protein |
| November 18 |
Study Published In Archives Of Surgery Demonstrated Benefit Of Entereg (Alvimopan) In Postoperative Ileus |
| November 18 |
Metabolex Announces Positive Results from Phase 2 Clinical Trial of MBX-8025 |
| November 18 |
XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain |
| November 18 |
New Publication Shows Angiomax Significantly Reduces Initial Hospital Costs by $572 Per Patient Compared to Conventional Therapy in Moderateand High-Risk ACS Patients |
| November 18 |
New Data Will Be Presented at ASH on Velcade (Bortezomib) for Injection-Based Therapies in Multiple Myeloma and Non-Hodgkin's Lymphoma |
| November 18 |
Research Provides Further Evidence for the Mechanism of Action Underlying Hythiam’s Prometa Treatment Program |
| November 18 |
Provectus Lead Investigator Professor John F. Thompson to Present at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting on November 19, 2008 |
| November 19 |
Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting |
| November 19 |
Elixir Pharmaceuticals’ Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not Well-Controlled on Metformin Alone |
| November 19 |
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer |
| November 19 |
Titan Pharmaceuticals Presents Phase 3 Data for Probuphine at the 2008 International Society of Addiction Medicine Congress |
| November 19 |
Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference |
| November 19 |
Pervasis Therapeutics Announces Promising Efficacy Results from Phase1 and 2 Clinical Trials of Vascugel® in Dialysis Patients Needing Permanent AV Access, Data Builds on Compelling Safety Findings |
| November 19 |
New Study Proves Protandim Produces 300% Increase in Glutathione, a Key Antioxidant and Anti-aging Factor |
| November 19 |
Helix BioPharma Presents Preclinical L-DOS47 Data at The Second Conference of Lung Cancer in Warsaw, Poland |
| November 19 |
Suven Life Sciences Presenting Biology Data of Their NCE’s at Society for Neuroscience Annual Meeting, SFN-2008 at Washington DC, USA |
| November 19 |
Phase III Studies Show That Vandetanib (Zactima) Brings Clinical Benefits to Patients With Lung Cancer |
| November 19 |
Bradmer to Present Poster on Progression Free Survival and Overall Survival Data from Neuradiab Phase II Trials at Society for Neuro-Oncology Meeting |
| November 19 |
Oxford BioMedica Announces Six-Month Efficacy Results With Low Dose of ProSavin in Phase I/II Trial in Parkinson’s Disease |
| November 19 |
Genfit New Phase I Clinical Trials with High-Dose Confirm the Excellent Tolerance of GFT505 in Healthy Volunteers |
| November 19 |
KAI Reports Positive Preclinical Results for KAI-1678, First-in-ClassCompound to Treat Pain |
| November 19 |
Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream |
| November 20 |
Lytix Presents LTX-109 Anti-Microbial Data at ICAAC |
| November 20 |
Alnylam Presents Pre-clinical Data from TTR Amyloidosis Development Program |
| November 20 |
Targacept Scientists Make Multiple Presentations at Society for Neuroscience Supporting the Potential of NNR Therapeutics to Treat CNSDiseases and Disorders |
| November 20 |
Provectus Lead Investigator Professor John F. Thompson Gives Update on PV-10 Melanoma Study at Clinical Oncological Society of Australia 2008 Annual Scientific Meeting |
| November 20 |
Gloucester Pharmaceuticals to Present Positive Results from Multiple Romidepsin Clinical Trials at the ASH Annual Meeting |
| November 20 |
Thought Leaders from Burzynski Research Institute, Inc. Present Encouraging Data on Antineoplastons for Treatment of Malignant Gliomas |
| November 20 |
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project |
| November 20 |
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology |
| November 21 |
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies |
| November 21 |
Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia |
| November 21 |
New Study Data: Januvia (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes |
| November 21 |
Burzynski Research Institute, Inc. (BRI) Presents Promising Phase II Data on Malignant Glioma |
| November 21 |
Iressa Proves Just as Effective as Chemotherapy for Lung Cancer Findings Represent First Time Oral Therapy Tested Head-to-Head Against Standard Therapy; Surprising Biomarker Results |
| November 21 |
Study shows GE Healthcare's Visipaque Associated with Lower Incidence of Contrast-Induced Nephropathy and Cardiovascular Events in Patients with Chronic Kidney Disease Compared to Iopromide |
| November 21 |
Transgene’s TG1042 meets primary end point in step one of cutaneous B-cell lymphoma Phase II trial |
| November 24 |
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile |
| November 24 |
Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented |
| November 24 |
ARIAD to Present Preclinical Data on Multi-Targeted Kinase Inhibitor at 50th Ash Annual Meeting |
| November 24 |
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results |
| November 24 |
Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections |
| November 24 |
Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase IIb Study |
| November 24 |
ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action |
| November 24 |
Largest-ever studies on most common form of adult leukemia, show patients treated with MabThera live longer without disease progressing |
| November 24 |
Testosterone Effective in Female Sexual Dysfunction; BioSante Conducting Long-Term Safety Study of LibiGel in FSD |
| November 24 |
Peregrine's Anti-Viral Bavituximab in Nature Medicine |
| November 24 |
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival in Advanced Breast Cancer |
| November 24 |
New Cancer Treatment Shrinks Pancreatic Tumor |
| November 24 |
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease |
| November 24 |
Labopharm to Host Webcast Presentation on Novel Trazodone Formulation for Treatment of Major Depressive Disorder |
| November 24 |
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C |
| November 24 |
Schering-Plough Unveils Top-Line Study Results for SAPHRIS (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention |
| November 24 |
Protox announces positive Phase 2 BPH results |
| November 25 |
Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology |
| November 25 |
ERYtech Pharma Presents a New Advance in the Treatment of Sickle Cell Anaemia |
| November 25 |
Aegera Therapeutics' Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 ASH Annual Meeting |
| November 25 |
Telcagepant Proven as a Safe and Effective Migraine Treatment in Phase III Trial |
| November 25 |
Press Release: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue |
| November 26 |
Stanford/Packard Study Shows No Benefit From Drug Widely Used to Prevent Premature Births |
| November 26 |
Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous Relistor for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain |
| November 26 |
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease |
| November 26 |
Growth hormone not beneficial for ALS |
| November 26 |
Flamel Technologies Update |
| November 26 |
Study Compares Strategies for BK Virus Nephropathy |
| November 26 |
Nitric Oxide Can Alter Brain Function |
